- Home
- CMMB vs MTEX Comparison
CMMB vs MTEX Comparison
Compare CMMB & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- MTEX
- Stock Information
- Founded
- CMMB 2004
- MTEX 1993
- Country
- CMMB Israel
- MTEX United States
- Employees
- CMMB N/A
- MTEX N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- MTEX Medicinal Chemicals and Botanical Products
- Sector
- CMMB Health Care
- MTEX Health Care
- Exchange
- CMMB Nasdaq
- MTEX Nasdaq
- Market Cap
- CMMB 23.0M
- MTEX 19.9M
- IPO Year
- CMMB N/A
- MTEX 1999
- Fundamental
- Price
- CMMB $1.21
- MTEX $11.79
- Analyst Decision
- CMMB Strong Buy
- MTEX
- Analyst Count
- CMMB 2
- MTEX 0
- Target Price
- CMMB $9.00
- MTEX N/A
- AVG Volume (30 Days)
- CMMB 89.3K
- MTEX 1.0K
- Earning Date
- CMMB 05-27-2025
- MTEX 05-13-2025
- Dividend Yield
- CMMB N/A
- MTEX N/A
- EPS Growth
- CMMB N/A
- MTEX N/A
- EPS
- CMMB N/A
- MTEX N/A
- Revenue
- CMMB N/A
- MTEX $115,036,000.00
- Revenue This Year
- CMMB N/A
- MTEX N/A
- Revenue Next Year
- CMMB N/A
- MTEX N/A
- P/E Ratio
- CMMB N/A
- MTEX N/A
- Revenue Growth
- CMMB N/A
- MTEX N/A
- 52 Week Low
- CMMB $0.60
- MTEX $6.75
- 52 Week High
- CMMB $2.55
- MTEX $16.49
- Technical
- Relative Strength Index (RSI)
- CMMB 46.51
- MTEX 65.65
- Support Level
- CMMB $1.15
- MTEX $9.70
- Resistance Level
- CMMB $1.31
- MTEX $11.97
- Average True Range (ATR)
- CMMB 0.09
- MTEX 0.34
- MACD
- CMMB -0.00
- MTEX 0.15
- Stochastic Oscillator
- CMMB 22.58
- MTEX 92.07
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.